Rinschen MM, Huesgen PF, Koch RE. The podocyte protease web: uncovering the gatekeepers of glomerular disease. Proteases regulate glomerular physiology. The last decade has revealed a multitude of podocyte proteases that govern the glomerular response to numerous chemical, mechanical, and metabolic cues. These proteases form a protein signaling web that integrates stress stimuli and serves as a key controller of the glomerular microenvironment. Both the extracellular and intracellular proteolytic networks are perturbed in focal segmental glomerulosclerosis, as well as hypertensive and diabetic nephropathy. Accordingly, the highly intertwined podocyte protease web is an integrative part of the podocyte's damage response. Novel mass spectrometry-based technologies will help to untangle this proteolytic network: functional readouts acquired from deep podocyte proteomics, single glomerular proteomics, and degradomics have exposed unanticipated protease activity in podocytes. Future efforts should characterize the interdependency and upstream regulation of key proteases, along with their role in promoting tissue heterogeneity in glomerular diseases. These efforts will not only illuminate the machinery of podocyte proteostasis but also reveal avenues for therapeutic intervention in the podocyte protease web.
INTRODUCTION
The renal filtration barrier is localized in the glomeruli and consists of three layers: the fenestrated endothelia, the glomerular basement membrane, and the podocytes. Mesangial cells provide structural support. Since the early 2000s, podocytes have emerged as the key cell type maintaining the renal filtration barrier. Podocytes are post-mitotic, neuron-like epithelial cells with a limited capacity for regeneration. They interdigitate via their foot processes and form specialized cell-cell contacts called slit diaphragms. Proteinuria, nephrotic syndrome, and focal segmental glomerulosclerosis (FSGS) result from podocyte injury and detachment (4) . In addition, the podocyte is damaged in diabetic and hypertensive nephropathy (16, 19, 25) .
Proteolytic processing of proteins is a crucial mechanism governing physiological and pathophysiological processes, such as differentiation, development, apoptosis, and cancer. Proteases are increasingly regarded as tailored therapeutic targets (38) . It has been known for more than a decade that intracellular protease activity is essential for physiological podocyte maintenance (1, 17, 32, 43) . The advent of novel mass spectrometry-based technologies has revealed the interdependence of various proteolytic systems in multiple fields, such as cancer and immunology. These advances brought about the concept of a "protease web" that controls cellular fate (9) . The aim of this review article is to provide an update on the physiological roles and functions of podocyte proteases ( Fig. 1 ), identify the cues that alter the podocyte protease web, and highlight novel technologies for the study of podocyte protease function.
INTRACELLULAR PROTEASES
Cathepsin proteases have long been implicated as disease drivers (1, 17, 32, 43) . Increased abundance of cathepsin L, an intracellular cysteine protease, is observed in a number of pathological glomerular states (11, 35) , since it promotes CD2-associated protein (Cd2ap) and synaptopodin proteolysis to drive podocyte damage and massive podocyte effacement (43) . Cathepsin abrogation is protective from a variety of external stimuli. Mechanistically, cathepsin L cleaves dynamin, which affects the regulation of actin cytoskeleton in foot processes (32) . More recently, it was found that cathepsin L knockout mice do not develop streptozotocin-induced glo-merular damage (although they develop diabetes), a finding that could also be related to protection of the endothelia (11) . Tissue cathepsin L can also be induced by cyclosporin in podocytes from cyclosporin A-treated patients (35) and correlates with proteinuria (6). However, cathepsin inhibition is not a general treatment in all conditions of glomerular disease. Blass et al. showed that using E-64, a broad and irreversible cysteine cathepsin inhibitor, did not reduce blood pressure or other aspects of glomerular injury that were induced by saltsensitive hypertension. This suggests that under hypertensive conditions, cathepsin inhibition may not be a sufficient strategy for reducing glomerular damage (3) . On the other hand, cathepsin D, an aspartic protease, is important for maintaining podocyte integrity, since cathepsin D-deficient mice develop slit diaphragm fragmentation, proteinuria, and end-stage renal disease (44) . Whereas loss of cathepsin L has a protective effect in mice, decreased cathepsin D appears to have a destructive effect. These studies underline the importance of distinguishing the roles of different cathepsins. Specific inhibitors that target particular cathepsins may lead to more effective therapies. Cathepsins contribute to both maintenance and acute injury response, and their widely studied functions place them at a pivotal node in the podocyte protease web.
Ubiquitin carboxyl-terminal hydrolase 40 (Usp40) and ubiquitin carboxyl-terminal hydrolase isozyme L1 (Uchl1) are two members of the family of ubiquitin proteases involved in sustaining podocyte integrity and linking proteases to podocyte proteostasis. Usp40 is an intermediate filament-associated ubiquitin protease (36) . Its expression is reduced in the puromycin aminonucleoside (PAN)-treated rat minimal change model, and zebrafish lacking the Usp40 ortholog demonstrate disruption of the renal filtration barrier (36) . Uchl1 is a ubiquitin protease that is normally absent from the kidney but highly expressed in damaged human podocytes (24) . Uchl1 deficiency, in contrast, leads to a strong glomerular phenotype that includes increased proteasome activity, a clear link to proteostasis (28) . Therefore, de novo expression of Uchl1 in injured podocytes appears to help restore proteasomal proteostasis. These studies thus far indicate the diverse capacity of ubiquitin proteases to affect the cytoskeletal and proteomic composition of podocytes. Calpain, a calcium-dependent cysteine protease, was originally identified as a protease that cleaved talin, an important focal adhesion molecule in the podocyte (37) . Recent evidence shows that calpain may be proteolytically processing calcineurin in vitro and potentially in vivo, as a smaller calcineurin fragment with unknown specificity and function was described (7) . However, in a rat model of FSGS, increased glomerular and urinary calpain activity were associated with enhanced calcineurin activity, reduced expression of the calpain target talin-1, and increased proteinuria. Treatment with the calpain inhibitor, calpeptin, prevented these effects (39) . This suggests that proteolytic turnover of focal adhesion proteins is a key process driving FSGS.
The caspase system is commonly used as a readout of glomerular injury, particularly among in vitro studies. For instance, inhibiting protease-activated receptor 2 (PAR2) using the FSLLRY-amide peptide reduced levels of damage markers caspase 9 and desmin in an in vitro model of podocyte damage (40) . High expression of transmembrane protein-16A (TMEM16A), a transmembrane protein in the P38/JNK signaling pathway, activates caspases 3 and 9 in cultured podocytes, implicating it as an agent of podocyte apoptosis in diabetic nephropathy (21) . Specifically in diabetic nephropathy, an alternative role for caspase 1 emerged in vivo. Caspase 1 is an intracellular cysteine-aspartic protease that regulates the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which is implicated in podocyte injury (33) . While a pharmacological caspase 3 inhibitor had no effect, a caspase 1 inhibitor blocked the progression of diabetic nephropathy. This suggests that the caspase 1-dependent inflammasome is a stronger contributor to diabetic nephropathy than mere apoptosis-related caspase signaling (33) . Interleukin-17 also activates caspase 1 (45) . These data show that caspase activity determines the balance between inflammasome and apoptosis, two fatedetermining events in glomerular biology.
EXTRACELLULAR PROTEASES
Extracellular matrix metalloproteases, thrombin, and complement form a microenvironment that is altered in glomerular disease states. Matrix metalloprotease 9 (MMP-9), a mesangial cell-expressed protease, controls podocyte differentiation (20) . Knockout of the membrane-bound metalloproteases meprin-␣ and -␤ leads to exacerbation of streptozotocin-induced diabetic nephropathy (5) . Angiotensin II reduces expression of MMP-2 and -9, and this can be reversed by Notch inhibition in vitro (46) . A focal increase in gelatinase activity and MMP-9 protein was observed in the glomeruli of diabetic rats (Zucker rats). Albumin administration resulted in a dose-dependent increase in MMP-9 protein and activity in culture supernatants of parietal epithelial cells in vitro (47) . These studies illuminate the various cues that regulate matrix metalloproteinases in kidney disease. Their role in modulating the glomerular extracellular matrix composition requires further studies.
Thrombin is a serine protease that interacts with PARs. PARs are expressed throughout the body; in the kidney, these G protein-coupled receptors have been found in mesangial cells and podocytes (31) . The function of PAR receptors activated by thrombin proteolysis has been recently reviewed (23, 27) . In the kidney, thrombin regulates glomerular filtration rate and renal hemodynamics via PARs. Moreover, elevated urinary thrombin is associated with glomerulonephritis and leads to PAR overstimulation, increased intracellular calcium levels, proteinuria, and deterioration of the glomerulus (8, 18) . Inhibition of thrombin with hirudin reduced proteinuria in two rat nephrosis models (34) . PAR1 antagonist Q94 (negative allosteric modulator of the PAR1 receptor) protects from doxorubicin-inflicted podocyte damage (12) . Future studies should continue to clarify the emerging function of thrombin and PARs in podocytes.
Taken together, the interplay between extracellular proteases, the microenvironment, and podocyte fate is not yet comprehensively characterized, but initial in vivo studies already show great promise for further interventional studies in proteinuric conditions. In addition, it will be important to identify the networks that result in proteolytic processing of important signaling molecules with direct relevance for podocyte biology, such as soluble urokinase plasminogen activator receptor (suPAR; 42) and Notch (26) .
NOVEL TECHNOLOGIES GENERATED INSIGHTS FOR THE PODOCYTE WEB
Recent technological advances have enabled the fast interrogation of molecular machinery within podocytes. A proteome and transcriptome atlas of the native podocyte identified 9,000 proteins and determined numerous novel podocyte-enriched proteins, including several disease candidates (29) . Among the podocyteenriched proteins were glutamyl aminopeptidase (Enpep), Usp13, carboxypeptidase Q (Cpq), neprilysin (Mme), pyroglutamyl peptidase 1 (Pgpep1), rhomboid-related protein-3 (Rhbdl3), dipeptidyl peptidase 4 (Dpp4), secernin-2 (Scrn2), serine protease HTRA1 (Htra1), mucosa-associated lymphoid tissue lymphoma translocation protein-1 homolog (Malt1), Scrn3, OTU domain-containing protein-7B (Otud7b), probable aminopeptidase NPEPL1 (Npepl1), disintegrin and metalloproteinase domain-containing protein-10 (Adam10), carboxypeptidase D (Cpd), and nardilysin (Nrd1). Some of these proteases have already been found in podocytes, e.g., Otud7b (also known as Cezanne), which is induced by ischemia in the kidney and in podocytes (22) . However, the majority of these proteases are functionally not characterized. An overarching finding is the high expression of peptidases in podocytes, a completely uncharacterized protein class in podocytes.
Glomerular diseases are heterogenous (14) . In a heterogenous disease, all glomeruli can be assumed to be at a different disease state, as demonstrated by emerging single-cell studies. Very recently, ultrasensitive proteomic analyses have been developed for single glomeruli-one glomerulus at a time (13) . Quantifying~50 glomeruli from 2 different FSGS mod-F1814 PODOCYTE PROTEASE WEB els, the lysosomal protein lysosome-associated membrane glycoprotein-1 (LAMP1) was positively correlated with markers of glomerular damage, including desmin, collagen-␣ 3 (IV) chain, and intraglomerular albumin. Moreover, abundance of cathepsin B, L, and Z were associated with LAMP1 abundance, and protein expression of all of these proteases were increased. Genetic deletion of cathepsin B and L, but not Z, ameliorated proteinuria induced by nephrotoxic serum. This suggests that the individual intrarenal correlation of proteome profiles can improve the prioritization of disease-associated proteases across the population of glomeruli (13) .
How can proteases be functionally characterized and linked to their substrates? Mass spectrometry-based degradomics is a key technology for analyzing podocyte function. Proteolytic cleavage generates new neo-NH 2 and neo-COOH termini in substrate proteins, but these are typically missed by standard proteomics approaches. Similar to other posttranslational modifications, dedicated protocols for enrichment of protein NH 2and/or COOH-terminal peptides have been developed to enable their identification and quantification on a proteome-wide scale (15) . Our recent N-degradomic analysis of podocytes revealed proteolytic processing of a variety of cytoskeletal and slit diaphragm proteins, including ␣-actinin-4, nephrin, podocin, and the intermediate filament protein vimentin (30) . Several of these novel proteoforms were dynamically altered by PANmediated podocyte injury in vitro and in vivo in Wilms tumor protein homolog heterozygous and PAN-treated rats. Analysis of cleavage sequence motifs and known interactions in the protease web provided insights into protease hierarchies (10) , which confirmed caspase activation in PAN-induced injury in vitro but not in vivo and revealed reduced processing by Arg-specific enzymes (30) . These approaches need to be further developed and applied to well-characterized models of podocyte injury.
CONCLUSION
Taken together, podocyte proteases are important for the physiological filtration barrier and autonomous integration of multiple cues. However, the network character of the proteases, as presented here (Fig. 1) , is not yet commonly acknowledged. Various sites appear to be specifically controlled and novel podocyte proteases have emerged in the proteome. Tight links exist to proteostasis and the microenvironment in diabetic, inflammatory, and sclerotic glomerular diseases. Comprehensive characterization of this podocyte protease web is not only informative but also necessary to decode the upstream metabolic and physiological cues of these programs. This should include both large-scale profiling of proteolytic processes and their (mis)regulation in kidney disease, as well as more detailed mechanistic studies of the role of individual proteases. Finally, spatial relationships need to be considered and analyzed. Collectively, this will complement ongoing efforts to model podocyte signaling networks (2, 41) . Therefore, it is fair to state that the function of the podocyte protease web is just beginning to be deciphered. 
